In a large randomized trial (the Breast Cancer International Research Group 006, BCIRG-6), patients with HER2-positive early breast cancer were assigned doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus trastuzumab (AC-TH), or TCbH; rates of disease-free survival at 5 years were 75, 84, and 81%, respectively, and rates of overall survival were 87, 92, and 91%, respectively [9]. The gene discussed is ERBB2; the disease is breast cancer.